newsfilter
← Latest News
Earnings Call Transcripts·

ALX Oncology - UBS Global Biopharma Conference - ALX ONCOLOGY HOLDINGS INC

  • Financial Performance:

    • The company reported being well-funded with cash reserves sufficient to sustain operations through mid-2028, following a $150 million capital raise in January.
    • No specific revenue, EPS, or profit margin figures were disclosed, as the call focused exclusively on clinical pipeline updates and strategic milestones.
    • The company is currently in a clinical development phase with no commercial products generating revenue yet.
  • Guidance and Future Outlook:

    • ALX2004 (EGFR ADC) Phase 1 data is expected to be disclosed in early December, prior to the company's holiday party.
    • EvorPRECEP (CD47) Phase 2 data in metastatic breast cancer is projected for the second half of 2027.
    • Management anticipates being on the "doorstep" of two registrational studies within the next 12 months if current execution continues.
    • Immediate focus shifts to expanding into second-line settings for both Head and Neck and Non-Small Cell Lung Cancer (NSCLC).
  • Business Segments and Product Lines:

    • ALX2004 (EGFR ADC): An in-house developed antibody-drug conjugate designed to minimize on-target toxicities (specifically rash) by utilizing a unique epitope from metuzumab. The Phase 1 study enrollment has been adjusted to target 35+ patients, with a specific focus on 15+ patients at optimal doses in non-small cell lung cancer and head and neck cancer.
    • EvorPRECEP (CD47): A CD47 inhibitor being evaluated in HER2-positive metastatic breast cancer. The ongoing Phase 2 (ASPEN-9) trial enrolls 120 HER2-positive patients to determine the optimal CD47 biomarker cutoff and assess efficacy in CD47-high vs. CD47-low subpopulations using an internal control design.
    • Strategic Shift: Moving from broad immune-oncology approaches to highly targeted biomarker-driven indications (CD47-high and HER2-positive).
  • Market and Competitive Landscape:

    • EGFR ADC Space: The EGFR target has historically failed due to skin toxicity (rash); competitors using cetuximab-derived constructs struggle with on-target effects. ALX distinguishes itself by using metuzumab to avoid wild-type EGFR on healthy skin.
    • Head and Neck: Emerging competition from bispecifics (e.g., PETO) moving to frontline use; ALX targets the post-PETO or refractory population, leveraging a different epitope to address potential resistance mutations.
    • NSCLC: Significant unmet need in squamous non-small cell lung cancer (wild-type), where other TROP2 ADCs (e.g., Adato DXd) have shown disappointing efficacy.
    • Breast Cancer: Current standard of care in the second-line HER2+ setting shows poor outcomes (14-15% ORR); ALX aims to double this rate by targeting CD47-high patients.
  • Risks and Challenges:

    • Toxicity Management: Despite design efforts to reduce rash, maintaining patient tolerability is critical; the goal is to reduce rash rates to under 15-20% (compared to >70% with cetuximab) to prevent dose discontinuation.
    • Biomarker Validation: Uncertainty remains regarding the precise CD47 overexpression cutoff for commercialization and ensuring robust HER2 re-prognosis via fresh biopsies or ctDNA.
    • Patient Population: Trials are recruiting heavily pre-treated patients (median 4th line in lung/head and neck), a difficult population with limited remaining therapeutic options.
    • Clinical Execution: Risk of dose-limiting toxicities (DLTs) related to the payload at higher dose levels (4 mg/kg).
  • Management Commentary and Tone:

    • Management (CEO Jason Letman) expressed high confidence and enthusiasm, describing the upcoming data as "inflection points" for the company.
    • The tone was optimistic, emphasizing the technical novelty of the metuzumab epitope and the potential for "transformational" response rates (>30%) in late-line settings.
    • Leadership highlighted the strategic advantage of avoiding skin toxicity and the unique ability to target mutations that may render other EGFR therapies ineffective.
  • Analyst Questions and Answers:

    • Question on EGFR Toxicity: Analyst asked if the drug eliminates rash. Management clarified that while non-human primate data showed no rash, human data is awaited, but the goal is a significant reduction in rash to keep patients on drug.
    • Question on Response Rates: Analyst questioned what constitutes a good response rate. Management stated double-digit rates are remarkable, >30% would be outstanding, and anything higher is transformative in a 4th-line setting.
    • Question on Biomarker Strategy: Analyst queried the study design regarding CD47 cutoffs. Management explained the Phase 2 is designed to internally control for efficacy by comparing CD47-high vs. CD47-low patients within the HER2+ population to validate the biomarker for Phase 3.
    • Question on Competition (PETO): Analyst asked about the impact of the emerging bispecific Peto. Management responded that ALX's different epitope (metuzumab vs. cetuximab) allows for efficacy in patients progressing on prior EGFR therapies.
  • Other Key Points:

    • The ALX2004 study will prioritize non-small cell lung cancer and head and neck cancer enrollment based on observed therapeutic range efficacy.
    • For the breast cancer trial, central confirmation of HER2 status is required, with ctDNA used as a backup for patients lacking fresh tissue; concordance rates for local vs. central testing are approximately 60-70%.
    • Management noted that the EGFR ADC field is competitive but emphasized the specific opportunity in the squamous lung and post-bispecific head and neck niches.
    • The company intends to disclose the ALX2004 data before the Christmas holiday period.
Company
ALX ONCOLOGY HOLDINGS INC
Keywords
ALX ONCOLOGY HOLDINGS INC